The cannabinoid system and immune modulation

Journal of Leukocyte Biology

Volumn 74, Issue 4, 2003, Pages 486-496

  Klein, Thomas W ^a,b   Newton, Cathy ^a   Larsen, Kellie ^a   Lu, Lily ^a   Perkins, Izabella ^a   Nong, Liang ^a   Friedman, Herman ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

CB1; Chemotaxis; G protein; Marijuana; Th1 cells; Tumor

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; CHEMOTAXIS; DRUG RECEPTOR BINDING; HELPER CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LONG TERM EXPOSURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOKING;

ANIMALS; CANNABINOIDS; CHEMOTAXIS; ENDOCANNABINOIDS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TETRAHYDROCANNABINOL;

ANIMALIA; CANNABIS; CANNABIS SATIVA;

EID: 0346350327     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0303101     Document Type: Review

References (121)

1. Coussens, L. M., Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867.
2. Harris, S. G., Padilla, J., Koumas, L., Ray, D., Phipps, R. P. (2002) Prostaglandins as modulators of immunity. Trends Immunol. 23, 144-150.
3. Miyaura, H., Iwata, M. (2002) Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J. Immunol. 168, 1087-1094.
4. Schneider, E., Rolli-Derkinderen, M., Arock, M., Dy, M. (2002) Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 23, 255-263.
5. Kohm, A. P., Sanders, V. M. (2001) Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol. Rev. 53, 487-525.
6. Eisenstein, T. K., Hilburger, M. E. (1998) Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83, 36-44.
7. Klein, T. W., Newton, C. A., Friedman, H. (2001) Cannabinoids and the immune system. Pain Res. Manag. 6, 95-101.
8. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202.
9. Adams, I. B., Martin, B. R. (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585-1614.
10. Joy, J. E., Watson, S. J., Benson, J. A. (1999) Marijuana and Medicine: Assessing the Science Base. Washington, DC, National Academy, 1-11.
11. Pertwee, R. G. (2002) Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95, 165-174.
12. Hollister, L. E. (1986) Health aspects of cannabis. Pharmacol. Rev. 38, 1-20.
13. Cabral, G., Dove Pettit, D. (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious diseases. J. Neuroimmunol. 83, 116-123.
14. Klein, T., Friedman, H., Specter, S. (1998) Marijuana, immunity and infection. J. Neuroimmunol. 83, 102-115.
15. Klein, T., Newton, C., Friedman, H. (1998) Cannabinoid receptors and immunity. Immunol. Today 19, 373-381.
16. Klein, T. W., Lane, B., Newton, C. A., Friedman, H. (2000) The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 225, 1-8.
17. Berdyshev, E. V. (2000) Cannabinoid receptors and the regulation of immune response. Chem. Phys. Lipids 108, 169-190.
18. Roth, M. D., Baldwin, G. C., Tashkin, D. P. (2002) Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids 121, 229-239.
19. Gaoni, Y., Mechoulam, R. (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647.
20. Howlett, A. C., Johnson, M. R., Melvin, L. S., Milne, G. M. (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33, 297-302.
21. Mechoulam, R., Feigenbaum, J. J., Lander, N., Segal, M., Jarbe, T. U. C., Hiltunen, A. J., Consroe, P. (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44, 762-764.
22. Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., Mitchell, R. L. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443-450.
23. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C., LeFur, G. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244.
24. Showalter, V. M., Compton, D. R., Martin, B. R., Abood, M. E. (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989-999.
25. Hillard, C. J., Manna, S., Greenberg, M. J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G., Campbell, W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289, 1427-1433.
26. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J., Vogel, Z. (1995) Identification of all endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
27. Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K. P., Fahey, K. J., Cullinan, G. J., Hunden, D. C., Johnson, D. W., Chaney, M. O., Koppel, G. A., Brownstein, M. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284, 291-297.
28. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J-C., LeFur, G. (1998) SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650.
29. Melvin, L., Johnson, M., Harbert, C., Milne, G., Weissman A. (1984) A cannabinoid derived prototypical analgesic. J. Med. Chem. 27, 67-71.
30. Bell, M. R., D'Ambra, T. E., Kumar, V., Eissenstat, M. A., Hermann, J. L., Wetzel, J. R., Rosi, D., Philion, R. E., Daum, S. J., Hlasta, D. J., Kullnig, R. K., Ackerman, J. H., Haubrich, D. R., Luttinger, D. A., Baizman, E. R., Miller, M. S., Ward, S. J. (1993) Antinociceptive (aminoalkyl)indoles. J. Med. Chem. 34, 1099-1110.
31. Huffman, J. W., Yu, S., Showalter, V., Abood, M. E., Wiley, J. L., Compton, D. R., Martin, B. R., Bramblett, R. D., Reggio, P. H. (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 39, 3875-3877.
32. Kuwae, T., Shiota, Y., Schmid, P. C., Krebsbach, R., Schmid, H. H. (1999) Biosynthesis and turnover of anandamide and other N-acylethanolamines in peritoneal macrophages. FEBS Lett. 459, 123-127.
33. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
34. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., Mechoulam, R. (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662-3665.
35. Felder, C. C., Nielsen, A., Briley, E. M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D. N., Richardson, J. M., Riggin, R. M., Koppel, G. A., Paul, S. M., Becker, G. W. (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393, 231-235.
36. Sugiura, T., Kobayashi, Y., Oka, S., Waku, K. (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids 66, 173-192.
37. Cravatt, B. E., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87.
38. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D., Hogestatt, E. D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
39. Devane, W. A., Dysarz III, F. A., Johnsem, M. R., Melvin, L. S., Howlett, A. C. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 606-613.
40. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., Bonner, T. I. (1990) Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
41. Gerard, C. M., Molhlereau, C., Vassart, G., Parmentier, M. (1991) Molecular cloning of a human canuabinoid receptor which is also expressed in testis. Biochem. J. 279, 129-134.
42. Chakrabarti, A., Onaivi, E., Chaudhuri, G. (1995) Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq. 5, 385-388.
43. Leroy, S., Griffon, N., Bourdel, M. C., Olie, J. P., Poirier, M. F., Krebs, M. O. (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 105, 749-752.
44. Munro, S., Thomas, K. L., Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
45. Shire, D., Calandra, B., Rinaldi-Carmona, M., Oustric, D., Pessegue, B., Bonnin-Cabanne, O., Le Fur, G., Caput, D., Ferrara, P. (1996) Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta 1307, 132-136.
46. Brown, S. M., Wager-Miller, J., Mackie, K. (2002) Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim. Biophys. Acta 1576, 255-264.
47. Ji, T. H., Grossmann, M., Ji, I. (1998) G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J. Biol. Chem. 273, 17299-17302.
48. Lefkowitz, R. J. (1998) G protein-coupled receptors. J. Biol. Chem. 273, 18677-18680.
49. Braun, M. C., Kelsall, B. L. (2001) Regulation of interleukin-12 production by G-protein-coupled receptors. Microbes Infect. 3, 99-107.
50. Rhee, M. H., Bayewitch, M., Avidor-Reiss, T., Levy, R., Vogel, Z. (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem. 71, 1525-1534.
51. Calandra, B., Portier, M., Kerneis, A., Delpech, M., Carillon, C., Le Fur, G., Ferrara, P., Shire, D. (1999) Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 374, 445-455.
52. Ho, B. Y., Current, L., Drewett, J. G. (2002) Role of intracellular loops of cannabinoid CB(1) receptor in functional interaction with G(alpha16). FEBS Lett. 522, 130-134.
53. Mackie, K., Lai, Y., Westenbrock, R., Mitchell, R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15, 6552-6561.
54. Garcia, D. E., Brown, S., Hille, B., Mackie, K. (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci. 18, 2834-2841.
55. Prevot, V., Rialas, C. M., Croix, D., Salzet, M., Dupouy, J. P., Poulain, P., Beauvillain, J. C., Stefano, G. B. (1998) Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res. 790, 236-244.
56. Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G., Casellas, P. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704-711.
57. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol. Pharmacol. 50, 334-341.
58. 9-tetrahydrocannabinol is mediated by nuclear factor κB and CB1 cannabinoid receptor. DNA Cell Biol. 16, 301-309.
59. Christie, M. J., Vaughan, C. W. (2001) Neurobiology cannabinoids act backwards. Nature 410, 527-530.
60. Barinaga, M. (2001) Neurobiology. How cannabinoids work in the brain. Science 291, 2530-2531.
61. Schlicker, E., Kathmann, M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565-572.
62. Kreitzer, A. C., Regehr, W. G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727.
63. Ohno-Shosaku, T., Maejima, T., Kano, M. (2001) Endogenous cannabinoids mediate retrograde signals front depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738.
64. Wilson. R. I., Nicoll, R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.
65. Baldwin, G. C., Tashkin, D. P., Buckley, D. M., Park, A. N., Dubinett, S. M., Roth, M. D. (1997) Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am. J. Respir. Crit. Care Med. 156, 1606-1613.
66. Shay, A. H., Choi, R., Whittaker K., Salehi, K., Kitchen, C. M., Tashkin, D. P., Roth, M. D., Baldwin, G. C. (2003) Impairment of antimicrobial activity and nitric oxide Production in alveolar macrophages from smokers of marijuana and cocaine. J. Infect. Dis. 187, 700-704.
67. Tindall, B., Cooper, D. A., Donovan, B., Barnes, T., Philpot, C. R., Gold, J., Penny, R. (1988) The Sydney AIDS project: development of acquired immunodeficieney syndrome in a group of HIV seropositive homosexual men. Aust. N. Z. J. Med. 18, 8-15.
68. Sidnev, S., Beck, J. E., Tekawa, I. S., Quesenberry, C. P., Friedmen, G. D. (1997) Marijuana use and mortality. Am. J. Public Health 87, 585-590.
69. Donald, P. J. (1986) Marijuana smoking-possible cause of head and neck carcinoma in young patients. Otolaryngol. Head Neck Surg. 94, 517-521.
70. Zhang, Z. F., Morgenstern, H., Spitz, M. R., Tashkin, D. P., Yu, G. P., Marshall, J. R., Hsu, T. C., Schantz, S. P. (1999) Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev. 8, 1071-1078.
71. Nong, L., Newton, C., Cheng, Q., Friedman, H., Roth, M. D., Klein, T. W. (2002) Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J. Neuroimmunol. 127, 169-176.
72. Daul, C. B., Heath, R. G. (1975) The effect of chronic marijuana usage on the immunological status of rhesus monkeys. Life Sci. 17, 875-882.
73. Cabral, G. A., Stinnett, A. L., Bailey, J., Ali, S. F., Paule, M. G., Scallet, A. C., Slikker, W. (1991) Chronic marijuana smoke alters alveolar macrophage morphology and protein expression. Pharmacol. Biochem. Behav. 40, 643-649.
74. Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., Schatz, A. R. (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42, 736-742.
75. Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., LeFur, G., Casellas, P. (1993) Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214, 173-180.
76. Daaka, Y., Klein, T. W., Friedman, H. (1995) Expression of cannabinoid receptor mRNA in murine and human leukocytes. In Advances in Experimental Medicine and Biology, vol. 373 (B. Sharp, T. K. Eisenstein, J. J. Madden, H. Friedman, eds.), New York, NY, Plenum, 91-96.
77. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T., Kaminski, N. E. (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenvlate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142, 278-287.
78. Noe, S. N., Newton, C., Widen, R., Friedman, H., Klein, T. W. (2000) Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. J. Neuroimmunol. 110, 161-167.
79. Sinha, D., Bonner, T. I., Bhat, N. R., Matsuda, L. A. (1998) Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J. Neuroimmunol. 82, 13-21.
80. Matias, I., Pochard, P., Orlando, P., Salzet, M., Pestel, J., Di Marzo, V. (2002) Presence and regulation of the endocannabinoid system in human dendritic cells. Eur. J. Biochem. 269, 3771-3778.
81. Daaka, Y., Friedman, H., Klein, T. W. (1996) Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J. Pharmacol. Exp. Ther. 276, 776-783.
82. Zimmer, A., Zimmer, A. M., Hohmann, W. G., Herkenham, M., Bonner, T. I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 5780-5785.
83. Galieque, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., Casellas, P. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61.
84. Lee, S. F., Newton, C., Widen, R., Friedman, H., Klein, T. W. (2001) Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur. J. Pharmacol. 423, 235-241.
85. Carlisle, S., Marciano-Cabral, F., Staab, A., Ludwick, C., Cabral, G. (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2, 69-82.
86. Carayon, P., Marchand, J., Dussossoy, D., Derocq, J. M., Jbilo, O., Bord, A., Bouaboula, M., Galiegue, S., Mondiere, P., Penarier, G., LeFur, G., Defrance, T., Casellas, P.(1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92, 3605-3615.
87. Zhuang, S., Kittler, J., Grigorenko, E. V., Kirby, M. T., Sim, L. J., Hampson, R. E., Childers, S. R., Deadwyler, S. A. (1998) Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res. Mol. Brain Res. 62, 141-149.
88. Gardner, B., Zu, L. X., Sharma, S., Liu, Q., Makriyannis, A., Tashkin, D. P., Dubinett, S. M. (2002) Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem. Biophys. Res. Commun. 290, 91-96.
89. 9-tetrahydrocannabinol, cytokines and immunity to Legionella pneumophila. Proc. Soc. Exp. Biol. Med. 209, 205-212.
90. 9-Tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci. 51, 151-160.
91. Schatz, A. R., Kessler, F. K., Kaminski, N. E. (1992) Inhibition of adenylate cyclase by 9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression. Life Sci. 51, PL25-PL30.
92. Kaminski, N., Koh, W. S., Yang, K. H., Lee, M., Kessler, F. K. (1994) Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem. Pharmacol. 48, 1899-1908.
93. Warner, J. F., Dennert, G. (1982) Effect of a clonal cell line with NK activity on bone marrow transplants, tumor development and metastasis in vivo. Nature (Lond.) 300, 31-34.
94. Yea, S. S., Yang, K. H., Kaminski, N. E. (2000) Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J. Pharmacol. Exp. Ther. 292, 597-605.
95. Condie, R., Herring, A., Koh, W. S., Lee, M., Kaminski, N. E. (1996) Cannabinoid induction of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem. 271, 13175-13183.
96. Faubert, B. L., Kaminski, N. E. (2000) AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J. Leukoc. Biol. 67, 259-266.
97. Trinchieri, G. (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146.
98. Cohen, M., Klein, E., Kuten, A., Fried, G., Zinder, O., Pollack, S. (2002) Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevated levels of stress hormones and decreased secretion of Th1 cytokines. Int. J. Cancer 100, 347-354.
99. Roy, S., Balasubramanian, S., Sumandeep, S., Charboneau, R., Wang, J., Melnyk, D., Beilman, G. J., Vatassery, R., Barke, R. A. (2001) Morphine directs T cells toward T(H2) differentiation. Surgery 130, 304-309.
100. Kohm, A. P., Sanders, V. M. (2000) Norepinepbrine: a messenger from the brain to the immune system. Immunol. Today, 21, 539-542.
101. Newton, C. A., Klein, T. W., Friedman, H. (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect. Immun. 62, 4015-4020.
102. 9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12, and IL-12 receptor β2 responses to Legionella pneumophila infection. J. Immunol. 164, 6461-6466.
103. Massi, P., Sacerdote, P., Ponti, W., Fuzio, D., Manfredi, B., Vigano, D., Rubino, T., Bardotti, M., Parolaro, D. (1998) Immune function alterations in mice tolerant to delta9-tetrahydrocannabinol: functional and biochemical parameters. J. Neuroimmunol. 92, 60-66.
104. Smith, S. R., Terminelli, C., Denhardt, G. (2001) Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur. J. Pharmacol. 425, 73-83.
105. Zhu, L. X., Sharma, S., Stolina, M., Gardner, B., Roth, M. D., Tashkin, D. P., Dubinett, S. M. (2000) Δ-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 165, 373-380.
106. Yuan, M., Kiertscher, S. M., Cheng, Q., Zoumalan, R., Tashkin, D. P., Roth, M. D. (2002) Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133, 124-131.
107. Szabo, I., Chen, X. H., Xin, L., Adler, M. W., Howard, O. M., Oppenheim, J. J., Rogers, T. J. (2002) Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. USA 99, 10276-10281.
108. Derocq, J. M., Jbilo, O., Bouaboula, M., Segui, M., Clere, C., Casellas, P. (2000) Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem. 275, 15621-15628.
109. Jorda, M. A., Verbakel, S. E., Valk, P. J., Vankan-Berkhoudt, Y. V., Maccarrone, M., Finazzi-Agro, A., Lowenberg, B., Delwel, R. (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786-2793.
110. Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23, 1398-1405.
111. Blazquez, C., Casanova, M. L., Planas, A., Del Pulgar, T. G., Villanueva, C., Fernandez-Acenero, M. J., Aragones, J., Huffman, J. W., Jorcano, J. L., Guzman, M. (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17, 529-531.
112. Schwarz, H., Blanco, F. J., Lotz, M. (1994) Anandamide, an endogenous cannabinoid receptor agonist, inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55, 107-115.
113. 9-Tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 286, 1103-1109.
114. Galve-Roperh, I., Sanchez, C., Cortes, M. L., del Pulgar, T. G., Izquierdo, M., Guzman, M. (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313-319.
115. Sanchez, C., de Ceballos, M. L., del Pulgar, T. G., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Hoffman, J. W., Ramon y Cajal, S., Guzman, M. (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784-5789.
116. Jacobsson, S. O., Wallin, T., Fowler, C. J. (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299, 951-959.
117. McKallip, R. J., Lombard, C., Fisher, M., Martin, B. R., Ryu, S., Grant, S., Nagarkatti, P. S., Nagarkatti, M. (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634.
118. De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., Di Marzo, V. (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 95, 8375-8380.
119. Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzman, M., Di Marzo, V. (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463, 235-240.
120. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., Di Marzo, V. (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126.
121. Recht, L. D., Salmonsen, R., Rosetti, R., Jang, T., Pipia, G., Kubiatowski, T., Karim, P., Ross, A. H., Zurier, R., Litofsky, N. S., Burstein, S. (2001) Antitumor effects of ajulemic acid (CT3), a synthetic, non-psychoactive cannabinoid. Biochem. Pharmacol. 62, 755-763.